Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butadiene SCHEMBL2767402 | 0.84 | CYP19A1 (0.35) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16434653 | 0.79 | CYP19A1 (0.39) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27396462 | 0.77 | NPC1 (0.38) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL2764665 | 0.74 | NPC1 (0.37) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL24117825 | 0.74 | NPC1 (0.38) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30730269 | 0.70 | KDM4E (0.35) | CYP19A1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19120962 | 0.69 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL9383085 | 0.69 | DDB1 (0.45) | CYP19A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL11826416 | 0.69 | PSMB8 (0.37) | CYP19A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27316660 | 0.67 | DDB1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266911-B1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | CYP19A1 622/4885NPC1 3681/4885RAB9A 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.